Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Acquired by Atika Capital Management LLC

Atika Capital Management LLC lifted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 40.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 136,500 shares of the company’s stock after purchasing an additional 39,500 shares during the period. Atika Capital Management LLC’s holdings in Kymera Therapeutics were worth $5,491,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Blue Trust Inc. boosted its position in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after buying an additional 270 shares during the period. Harbor Capital Advisors Inc. boosted its holdings in Kymera Therapeutics by 1.7% in the fourth quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock valued at $1,649,000 after purchasing an additional 684 shares during the period. KBC Group NV grew its stake in Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Kymera Therapeutics by 8.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,289 shares of the company’s stock worth $534,000 after purchasing an additional 915 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Kymera Therapeutics by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,733 shares of the company’s stock worth $552,000 after purchasing an additional 1,311 shares during the period.

Insider Activity at Kymera Therapeutics

In related news, COO Jeremy G. Chadwick sold 1,383 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now owns 67,800 shares in the company, valued at $2,064,510. The trade was a 2.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Ellen Chiniara sold 2,241 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the sale, the insider now directly owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 13,788 shares of company stock worth $455,202 in the last 90 days. 15.82% of the stock is owned by insiders.

Kymera Therapeutics Stock Performance

KYMR opened at $22.07 on Friday. Kymera Therapeutics, Inc. has a one year low of $21.40 and a one year high of $53.27. The stock has a market capitalization of $1.43 billion, a P/E ratio of -9.43 and a beta of 2.22. The business’s 50-day simple moving average is $34.02 and its 200-day simple moving average is $41.02.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The firm had revenue of $7.39 million during the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KYMR has been the subject of several recent research reports. HC Wainwright lifted their price objective on Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Stephens reiterated an “overweight” rating and set a $60.00 price target on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Leerink Partners restated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. BTIG Research started coverage on shares of Kymera Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective for the company. Finally, Citigroup began coverage on Kymera Therapeutics in a report on Thursday, March 13th. They issued a “buy” rating and a $52.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $56.36.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.